Genotoxic effects of doxorubicin in cultured human lymphocytes with different glutathione S-transferase genotypes

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 724, Issue 1-2, 2011, Pages 28-34

  Ramos, D L ^a,b   Gaspar, J F ^b   Pingarilho, M ^b   Gil, O M ^b,c   Fernandes, A S ^a,b   Rueff, J ^b   Oliveira, N G ^a,b  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^c INSTITUTO TECNOLÓGICO E NUCLEAR   (Portugal)

Author keywords

Doxorubicin; Genetic polymorphisms; Glutathione S transferases; Micronuclei

Indexed keywords

(1 BUTYLAMINO 3 METHYLBUTYL)(1 PYRROLIDINYL) KETONE; DOXORUBICIN; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1;

ADULT; ARTICLE; BLOOD CULTURE; CELL DIVISION; CLINICAL ARTICLE; CYTOKINESIS; FEMALE; GENE DELETION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTOXICITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LYMPHOCYTE; MALE; MICRONUCLEUS TEST; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; CELL DIVISION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; LYMPHOCYTES; MALE; MICRONUCLEUS TESTS; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 79961021312     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2011.04.013     Document Type: Article

References (40)

1. Lal S., Mahajan A., Chen W.N., Chowbay B. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr. Drug Metab. 2010, 11:115-128.
2. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57:727-741.
3. Cortés-Funes H., Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc. Toxicol. 2007, 7:56-60.
4. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56:185-229.
5. Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog. Cardiovasc. Dis. 2007, 49:330-352.
6. Fernandes A.S., Serejo J., Gaspar J., Cabral F., Bettencourt A.F., Rueff J., Castro M., Costa J., Oliveira N.G. Oxidative injury in V79 Chinese hamster cells: protective role of the superoxide dismutase mimetic MnTM-4-PyP. Cell Biol. Toxicol. 2010, 26:91-101.
7. Tan H.H., Porter A.G. DNA methyltransferase I is a mediator of doxorubicin-induced genotoxicity in human cancer cells. Biochem. Biophys. Res. Commun. 2009, 382:462-467.
8. Deng S., Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc. Toxicol. 2007, 7:129-134.
9. Stearns V., Davidson N.E., Flockhart D.A. Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J. 2004, 4:143-153.
10. Lo H.-W., Ali-Osman F. Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr. Opin. Pharmacol. 2007, 7:367-374.
11. Hu X., O'Donnell R., Srivastava S.K., Xia H., Zimniak P., Nanduri B., Bleicher R.J., Awasthi S., Awasthi Y.C., Ji X., Singh S.V. Active site architecture of polymorphic forms of human glutathione S-transferase P1-1 accounts for their enantioselectivity and disparate activity in the glutathione conjugation of 7β 8α-dihydroxy-9α,10α-oxy-7,8,9,10-tetrahydrobenzo(a)pyr ene. Biochem. Biophys. Res. Commun. 1997, 235:424-428.
12. Harries L.W., Stubbins M.J., Forman D., Howard G.C.W., Wolf C.R. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997, 18:641-644.
13. Garte S, Gaspari L., Alexandrie A.-K., Ambrosone C., Autrup H., Autrup J.L., Baranova H., Bathum L., Benhamou S., Boffetta P., Bouchardy C., Breskvar K., Brockmoller J., Cascorbi I., Clapper M.L., Coutelle C., Daly A., Dell'Omo M., Dolzan V., Dresler C.M., Fryer A., Haugen A., Hein D.W., Hildesheim A., Hirvonen A., Hsieh L.L., Ingelman-Sundberg M., Kalina I., Kang D., Kihara M., Kiyohara C., Kremers P., Lazarus P., Le Marchand L., Lechner M.C., van Lieshout E.M.M., London S., Manni J.J., Maugard C.M., Morita S., Nazar-Stewart V., Noda K., Oda Y., Parl F.F., Pastorelli R., Persson I., Peters W.H.M., Rannug A., Rebbeck T., Risch A., Roelandt L., Romkes M., Ryberg D., Salagovic J., Schoket B., Seidegard J., Shields P.G., Sim E., Sinnet D., Strange R.C., Stücker I., Sugimura H., To-Figueras J., Vineis P., Yu M.C., Taioli E. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomarkers Prev. 2001, 10:1239-1248.
14. Gaspar J., Rodrigues S., Gil O.M., Manita I., Ferreira T.C., Limbert E., Gonçalves L., Pina J.E., Rueff J. Combined effects of glutathione S-transferase polymorphisms and thyroid cancer risk. Cancer Genet. Cytogenet. 2004, 151:60-67.
15. de Jong M.M., Nolte I.M., te Meerman G.J., van der Graaf W.T., de Vries E.G.E., Sijmons R.H., Hofstra R.M.W., Kleibeuker J.H. Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 2002, 11:1332-1352.
16. Beaumont P.O., Moore M.J., Ahmad K., Payne M.M., Lee C., Riddick D.S. Role of glutathione S-transferases in the resistance of human colon cancer cell lines to doxorubicin. Cancer Res. 1998, 58:947-955.
17. Goto S., Ihara Y., Urata Y., Izumi S., Abe K., Koji T., Kondo T. Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase π FASEB J. 2001, 15:2702-2714.
18. Huang G., Mills L., Worth L.L. Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells. Mol. Cancer Ther. 2007, 6:1610-1619.
19. Gaudiano G., Koch T.H., Lo Bello M., Nuccetelli M., Ravagnan G., Serafino A., Sinibaldi-Vallebona P. Lack of glutathione conjugation to adriamycin in human breast cancer MCF-7/DOX cells. Inhibition of glutathione S-transferase p1-1 by glutathione conjugates from anthracyclines. Biochem. Pharmacol. 2000, 60:1915-1923.
20. O'Brien M., Kruh G.D., Tew K.D. The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J. Pharmacol. Exp. Ther. 2000, 294:480-487.
21. Lin D.-X, Tang Y.-M., Peng Q., Lu S.-X., Ambrosone C.B., Kadlubar F.F. Susceptibility to esophageal cancer and genetic polymorphisms in glutathione-S-transferase T1, P1 and M1 and cytochrome P450 2E1. Cancer Epidemiol. Biomarkers Prev. 1998, 7:1013-1018.
22. Gil O.M., Oliveira N.G., Rodrigues A.S., Laires A., Ferreira T.C., Limbert E., Rueff J. Possible transient adaptive response to mitomycin C in peripheral lymphocytes from thyroid cancer patients after iodine-131 therapy. Int. J. Cancer 2002, 102:556-561.
23. Fenech M. The in vitro micronucleus technique. Mutat. Res. 2000, 455:81-95.
24. Oliveira N.G., Castro M., Rodrigues A.S., Gonçalves I.C., Martins C., Toscano Rico J.M., Rueff J. Effect of poly(ADP-ribosyl)ation inhibitors on the genotoxic effects of the boron neutron capture reaction. Mutat. Res. 2005, 583:36-48.
25. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs, vols. 1-42 (Suppl. 7), Adryamicin, 1987, p. 81.
26. Dhawan A., Kayani M.A., Parry J.M., Parry E., Anderson D. Aneugenic and clastogenic effects of doxorubicin in human lymphocytes. Mutagenesis 2003, 18:487-490.
27. Amara-Mokrane Y.A., Lehucher-Michel M.P., Balansard G., Duménil G., Botta A. Protective effects of α-hederin, chlorophyllin and ascorbic acid towards the induction of micronuclei by doxorubicin in cultured human lymphocytes. Mutagenesis 1996, 11:161-167.
28. Rueff J, Chiapella C., Chipman J.K., Darroudi F., Silva I.D., Duverger-van Bogaert M., Fonti E., Glatt H.R., Isern P., Laires A., Léonard A., Llagostera M., Mossesso P., Natarajan A.T., Palitti F., Rodrigues A.S., Schinoppi A., Turchi G., Werle-Schneider G. Development and validation of alternative metabolic systems for mutagenicity testing in short-term assays. Mutat. Res. 1996, 353:151-176.
29. Schrijvers D. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin. Pharmacokinet. 2003, 42:779-791.
30. Jagetia G.C., Nayak V. Effect of doxorubicin on cell survival and micronuclei formation in HeLa cells exposed to different doses of gamma-radiation. Strahlenther. Onkol. 2000, 176:422-428.
31. Jagetia G.C., Aruna R. Correlation of micronuclei-induction with the cell survival in HeLa cells treated with a base analogue, azidothymidine (AZT) before exposure to different doses of gamma-radiation. Toxicol. Lett. 2003, 139:33-43.
32. Pathak R., Dey S.K., Sarma A., Khuda-Bukhsh A.R. Genotoxic effects in M5 cells and Chinese hamster V79 cells after exposure to 7Li-beam (LET=60keV/microm) and correlation of their survival dynamics to nuclear damages and cell death. Mutat. Res. 2007, 628:56-66.
33. Autrup J.L., Hokland P., Pedersenand L., Autrup H. Effect of glutathione S-transferases on the survival of patients with acute myeloid leukaemia. Eur. J. Pharmacol. 2002, 438:15-18.
34. Cho H.J., Eom H.S., Kim H.J., Kim I.S., Lee G.W., Kong S.Y. Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. Cancer Genet. Cytogenet. 2010, 198:40-46.
35. Sweeney C., McClure G.Y., Fares M.Y., Stone A., Coles B.F., Thompson P.A., Korourian S., Hutchins L.F., Kadlubar F.F., Ambrosone C.B. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res. 2000, 60:5621-5624.
36. Harbottle A., Daly A.K., Atherton K., Campbell F.C. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int. J. Cancer 2001, 92:777-783.
37. Duvoix A., Schnekenburger M., Delhalle S., Blasius R., Borde-Chiché P., Morceau F., Dicato M., Diederich M. Expression of glutathione S-transferase P1-1 in leukemic cells is regulated by inducible AP-1 binding. Cancer Lett. 2004, 216:207-219.
38. Dasgupta R.K., Adamson P.J., Davies F.E., Rollinson S., Roddam P.L., Ashcroft A.J., Dring A.M., Fenton J.A., Child J.A., Allan J.M., Morgan G.J. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 2003, 102:2345-2350.
39. Bonassi S., Znaor A., Ceppi M., Lando C., Chang W.P., Holland N., Kirsch-Volders M., Zeiger E., Ban S., Barale R., Bigatti M.P., Bolognesi C., Cebulska-Wasilewska A., Fabianova E., Fucic A., Hagmar L., Joksic G., Martelli A., Migliore L., Mirkova E., Scarfi M.R., Zijno A., Norppa H., Fenech M. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis 2007, 28:625-631.
40. Allan J.M., Wild C.P., Rollinson S., Willett E.V., Moorman A.V., Dovey G.J., Roddam P.L., Roman E., Cartwright R.A., Morgan G.J. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:11592-11597.